PubMed Health⌕ Search

Biomedical subjects

J Fayette

Publications and source records attributed to J Fayette.

15 recordsLinked to original sources
PubMed2005

[Chemotherapy of sarcomas: optimization of existing drugs and new molecules].

Chemotherapy of sarcomas includes two major drugs: doxorubicin, ifosfamide and a third, dacarbazine, whose effectiveness remains marginal. The current challenge consists in improving the combination of these drugs, in particular by modulating their amounts. New molecules of chemotherapy show their efficiency in sarcomas. Among those, one will note above all gemcitabine and ET-743, in some sub-types. Target therapies and antiangiogenic treatment have also begun to show results. It is advisable from now on to distinguish the different sub-type of sarcomas in order to assess cytotoxic activity.

Antineoplastic Agents↗
PubMed2005

[Soft tissues sarcomas: good medical practices for an optimal management].

The soft tissue sarcomas are a rare pathology and patient management complex. Good clinical practice should be delineated by rigorous recommendations. In case of suspicion of a sarcoma, precise assessment imagery must be carried out with a biopsy to allow the preparation of the surgical procedure. The surgical procedure should be extensive and complete to enable a macroscopic and microscopic resection. The adjuvant treatment could involve radiotherapy and chemotherapy whose indications should be specified within a multidisciplinary team. Unfortunately, recent studies showed no optimal management for majority of patients treated for sarcomas.

Combined Modality Therapy↗
PubMed2005

[Targeting angiogenesis in oncology].

Advances in biology have lead to the characterization of the molecular mechanisms underlying angiogenesis, a crucial process of tumor growth. Tumor cells secrete various growth factors, including VEGF, which activate endothelial cells to form new blood vessels. Numerous drugs, at present in clinical development, interfere with the molecular mediators of angiogenesis. The death of neovessels achieved by some of such compounds allows reduction in tumor size. This review describes many angiogenesic inhibitors which mechanisms of action are quite diverse.

Angiogenesis Inducing Agents↗
PubMed1998

Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes.

Dendritic cells (DC) are potent APCs initiating immune responses. In a previous report, we demonstrated that DC directly enhance both proliferation and differentiation of CD40-activated naive and memory B cells. The present study deciphers the molecular mechanisms involved in DC-dependent regulation of B cell responses. Herein, we have identified IL-12 as the mandatory molecule secreted by CD40-activated DC that promote the differentiation of naive B cells into plasma cells secreting high levels of IgM. In fact, IL-12 synergizes with soluble IL-6R alpha-chain (sgp80), produced by DC, to drive naive B cell differentiation. IL-12 is critical for the differentiation of naive B cells into IgM plasma cells, whereas IL-6R signaling mainly promotes Ig secretion by already differentiated B cells. The differentiation of naive B cells in cocultures of B cells, T cells, and DC is IL-12 dependent, definitely demonstrating that the role of DC in humoral responses is not confined to the activation of T cells and further extending the physiologic relevance of DC/B cell interaction. Finally, this study also identifies differential requirements for DC-dependent naive and memory B cell differentiation, the latter being IL-12 independent. Altogether these results indicate that, in addition to prime T cells toward Thl development, DC, through the production of IL-12, may also directly signal naive B cell during the initiation of the immune response.

Antibodies, Blocking↗
PubMed1998

Dendritic cells enhance the differentiation of naïve B cells into plasma cells in vitro.

We have shown previously that in vitro-generated human dendritic cells have an effect on the response of B cells at various stages of their differentiation. In a culture system described for the in vitro induction of plasma-cell differentiation, it was reported that naïve B cells have a poor propensity to differentiate into plasma cells. In such a culture system, 12% of naïve B cells differentiated into plasma cells in the presence of IL-2 and IL-10, despite the interruption of CD40 signalling which is necessary for plasma-cell differentiation. However, as reported herein, naïve B cells differentiated fully into plasma cells in response to dendritic cells. Addition of dendritic cells enhanced this differentiation strikingly by recruiting 57% of B cells as plasma cells producing IgM, but also IgG and IgA. In this model, dendritic cells act in synergy with IL-2 at an early stage of CD40-dependent B-cell differentiation, while IL-2 and IL-10 act together, at a later stage, in the generation of plasma cells in a CD40-independent manner. Thus, in addition to the key role played by dendritic cells in the initiation of T-cell responses, our results suggest that dendritic cells regulate humoral responses.

B-Lymphocytes↗
PubMed1997

Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2.

Within T cell-rich areas of secondary lymphoid organs, interdigitating dendritic cells recruit antigen-specific T cells that then induce B cells to secrete Igs. This study investigates the possible role(s) of dendritic cells in the regulation of human B cell responses. In the absence of exogenous cytokines, in vitro generated dendritic cells (referred to as Dendritic Langerhans cells, D-Lc) induced surface IgA expression on approximately 10% of CD40-activated naive sIgD+ B cells. In the presence of IL-10 and TGF-beta, a combination of cytokines previously identified for its capacity to induce IgA switch, D-Lc strongly potentiated the induction of sIgA on CD40-activated naive B cells from 5% to 40-50%. D-Lc alone did not induce the secretion of IgA by CD40-activated naive B cells, which required further addition of IL-10. Furthermore, D-Lc skewed towards the IgA isotype at the expense of IgG, the Ig production of CD40-activated naive B cells cultured in the presence of IL-10 and TGF-beta. Importantly, under these culture conditions, both IgA1 and IgA2 were detected. In the presence of IL-10, secretion of IgA2 by CD40-activated naive B cells could be detected only in response to D-Lc and was further enhanced by TGF-beta. Collectively, these results suggest that in addition to activating T cells in the extrafollicular areas of secondary lymphoid organs, human D-Lc also directly modulate T cell-dependent B cell growth and differentiation, by inducing the IgA isotype switch.

Antigens, CD34↗
PubMed1997

Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes.

After antigen capture, dendritic cells (DC) migrate into T cell-rich areas of secondary lymphoid organs, where they induce T cell activation, that subsequently drives B cell activation. Here, we investigate whether DC, generated in vitro, can directly modulate B cell responses, using CD40L-transfected L cells as surrogate activated T cells. DC, through the production of soluble mediators, stimulated by 3- to 6-fold the proliferation and subsequent recovery of B cells. Furthermore, after CD40 ligation, DC enhanced by 30-300-fold the secretion of IgG and IgA by sIgD- B cells (essentially memory B cells). In the presence of DC, naive sIgD+ B cells produced, in response to interleukin-2, large amounts of IgM. Thus, in addition to activating naive T cells in the extrafollicular areas of secondary lymphoid organs, DC may directly modulate B cell growth and differentiation.

Animals↗